Croda International, the Goole-quartered speciality chemicals company, has chalked up two technology acquisitions in its novel application areas.
Its technology acquisition programme supplements its development of new opportunities through organic investment and open innovation. Over the last year, it has completed four technology acquisitions and co-investments.
Nautilus Biosciences Canada is a tech-rich marine biotechnology company based in Charlottetown, Canada.
Founded in 2007, Nautilus focuses on using marine microbial biodiversity to discover novel actives and materials. Through this acquisition and the associated patents, Croda will utilise this innovative science for applications across all its market sectors.
The two companies have worked closely together for the past six years developing specific applications for skin care and hair care, as well as crop care.
Croda intends to establish Nautilus as a Croda centre of innovation for Marine Biotechnology at Nautilus’ existing base at the University of Prince Edward Island.
Croda has also completed the acquisition of IonPhasE Oy, an innovative tech supplier of static electricity protection products, headquartered in Tampere, Finland.
Operating in some of the fastest growing segments within the plastics market, IonPhasE has developed a unique range of anti-static additives that help to prevent damage to electrical components, increase the safety of chemical and food packaging and improve the long-term appearance of consumer appliances.
Focused on Electrostatic Discharge Protection (ESD) and Inherently Dissipative Polymers (IDPs), IonPhasE’s products use the most advanced technologies in the static electricity protection market, which work to release static electricity in a controlled way.
These acquisitions follow the purchase of Enza Biotech AB in July 2017, a research enterprise in Sweden aiming to develop the next generation of renewable surfactants, together with an investment in Cutitronics, a UK tech-based innovator of personalised, adaptive skin care.
Steve Foots, Chief Exec of Croda, said: “With Nautilus as part of the Croda group, we further expand our expertise in biotechnology; the Nautilus team that will join us have extensive knowledge and expertise in marine biotechnology, also known as “blue biotechnology”.
“The experience and knowledge of the IonPhasE management team, coupled with our innovation strength, global sales reach and complementary technologies, will allow us to better meet the needs of our customers within our Smart Materials business within the Performance Technologies sector.”